| Altais Medical Group - Riverside, Inc. | |
|
4646 Brockton Ave Ste 201 And 202 Riverside CA 92506-0102 | |
| (626) 840-1359 | |
| Not Available |
| Full Name | Altais Medical Group - Riverside, Inc. |
|---|---|
| Speciality | General Practice |
| Location | 4646 Brockton Ave, Riverside, California |
| Authorized Official Name and Position | Dilip Parekh (DIRECTOR/PRESIDENT) |
| Authorized Official Contact | 9515851800 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Altais Medical Group - Riverside, Inc. 4646 Brockton Ave Ste 201 Riverside CA 92506-0104 Ph: (206) 617-4000 | Altais Medical Group - Riverside, Inc. 4646 Brockton Ave Ste 201 And 202 Riverside CA 92506-0102 Ph: (626) 840-1359 |
| NPI Number | 1518629575 |
|---|---|
| Provider Enumeration Date | 10/07/2021 |
| Last Update Date | 02/03/2022 |
| Medicare PECOS PAC ID | 8628465424 |
|---|---|
| Medicare Enrollment ID | O20220426001502 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518629575 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | William M Suh |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1740200351 PECOS PAC ID: 5496790891 Enrollment ID: I20050627000435 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Sarah Chae |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003872169 PECOS PAC ID: 7719908250 Enrollment ID: I20060329000309 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | David M Choi |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1912981598 PECOS PAC ID: 2062519861 Enrollment ID: I20070511000487 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Rodolfo E Saenz |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1538165196 PECOS PAC ID: 7719084367 Enrollment ID: I20070516000541 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Colin C Christensen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518118298 PECOS PAC ID: 6103952098 Enrollment ID: I20100330000998 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Eric M Choi |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1841406568 PECOS PAC ID: 2365575503 Enrollment ID: I20100809000525 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Clara Ji Chae |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1861697427 PECOS PAC ID: 7416141403 Enrollment ID: I20140620001362 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Kathleen L Keating |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679839005 PECOS PAC ID: 8820391196 Enrollment ID: I20160120000909 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Howard Aubert |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1912116989 PECOS PAC ID: 3678768223 Enrollment ID: I20161108001229 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
| Provider Name | Leah Gail Hopkins |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548239932 PECOS PAC ID: 0446152078 Enrollment ID: I20181009001748 |
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
News Archive
Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.
A program encouraging overweight or obese adolescents to increase their physical activity through use of their everyday environment, rather than organized classes or sports programs, produced significant increases in participants' daily physical activity that were sustained for at least three to four months.
Oncolytics Biotech Inc. announced today that a poster presentation covering updated results of its Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers was presented today at the ASCO 2010 Annual Meeting in Chicago, IL.
TRICARE West Region beneficiaries can assist military families and help save the environment with a simple click of a mouse. February 4 through March 31, 2011, when a TRICARE beneficiary chooses to "Go Green" and opts-in for paperless statements, TriWest will contribute $5 to a military support organization. The beneficiary may choose to direct TriWest's contribution to Armed Services YMCA, Operation Homefront, Tragedy Assistance Program for Survivors or the USO.
› Verified 3 days ago
Innovative Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4500 Brockton Ave Ste 305, Riverside, CA 92501 Phone: 206-445-9978 Fax: 858-280-3279 | |
Pulmonary Partners Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5790 Magnolia Ave, Suite 201, Riverside, CA 92506 Phone: 951-368-0427 Fax: 951-368-0429 | |
Lyn M Pintelon D.o. Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8990 Garfield St, Ste.6, Riverside, CA 92503 Phone: 951-358-0784 Fax: 951-354-7583 | |
Precision Spinal Care Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4224 Cedar Pine Ct, Riverside, CA 92505 Phone: 909-648-0377 | |
Parkview Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3722 Tibbetts St, Riverside, CA 92506 Phone: 951-784-3770 | |
Orangecrest Medical Group, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4646 Brockton Ave Ste 203, Riverside, CA 92506 Phone: 951-774-2881 Fax: 951-774-2846 | |
Harmony Health Solutions Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5750 Division St Ste 208, Riverside, CA 92506 Phone: 310-560-9292 |